

# 8<sup>th</sup> international workshop on PET in lymphoma and myeloma (PILM 2021)

All sessions available during the meeting and few days afterwards for experts.



**VIRTUAL MEETING**

**Friday september 10<sup>th</sup>**

**Afternoon sessions (on-line) start 2.00 pm (CEST)**

2.00 pm: **Opening :**

**M Meignan (France), A Gallamini (France)**

**F Morschhauser (LYSA), F Merli (FIL),**

**L Guerra (Italy) , C Haioun (France), C Thieblemont(France)**

**2.15- 3.15: International project of MTV Harmonization**

**Chair: I Buvat (France),S Barrington (UK), M Meignan (France).**

**Panel involved in the project:** I Buvat (France),R Boellaard (Netherlands), L Ceriani (Switzerland) S Chauvie (Italy), G Mikhaeel (UK), O Casasnovas (France),AS Cottereau (France), A Berriolo (France), A Gallamini (France), C Schmitz (Germany), C Kobe (Germany), L Kostakoglu (USA), T El Galaly (Denmark), A Moskowitz (US), H Schoder (US), A Versari (Italy), L Guerra (Italy), S Luminari (Italy), L Rigacci (Italy), L Ceriani (Switzerland), E Zucca (Switzerland)

25 min presentation (summary of the Expert session and proposed guidelines):

M.Meignan (France), I.Buvat (France), C Thieblemont (France), S.Barrington (UK), R Boellaard (Netherlands)

Questions from the audience: 35 min. Chair: E.Zucca,

**Video of the expert session (08/27/2021) available on-line**

### **3.30- 4.30 Imaging and MRD in Myeloma**

**Chair: S Luminari (Italy), C.Haioun (France)**

**Panel:** P Moreau (France), J San Miguel (Spain), A Versari (Italy), C Nanni (Italy), F Bodere (France) .

**E Zamagni** : 30 min.

Discussion with the panel: 30 min

### **4.30-6.00 CAR-T cell: what is expected from PET imaging?**

**Chair: S Schuster (USA), C Thieblemont (France)**

**Panel:** S Schuster (US), C Thieblemont (France), I Buvat (France), AS Cottreau (France), H Schoder (USA), L Vercellino (France), A Moskowitz (USA), K Hermann (Germany), A Alizadeh (USA), C.Millin (France)

**S Schuster:** 30 min

**C Thieblemont:** 30 min

Discussion with the panel: 30 min.

Topics which could be addressed:

- Is pseudoprogression an issue after CAR T-cells ? VERCELLINO/MILIN
- May early TEP before D30 be beneficial for the patients? If yes, why and when? MOSKOWITZ
- May heterogeneity of TEP capture the immunology BUVAT
- Ct DNA / TEP: same prognostic value? ALIZADEH

## **Break**

### **Evening sessions (on-line)**

#### **8.00-9.00. TMTV and DNA in lymphoma**

**Chair: D Rossi (Italy), AS Cottreau (France)**

**Panel:** A Gallamini (France), C Rossi (France), O Casasnovas (France), C Kobe (Germany), Ch Schmitz (Germany), M Meignan ( France)

40 min: **A. Alizadeh:** new data and perspectives

Discussion with the panel:20 min.

## **9.00-10.00. How to define prognostic indices including baseline PET parameters? (Debate)**

**Chair: L Sehn (CND), E Zucca (Switzerland)**

**Panel: L Ceriani (Switzerland), C Thieblemont (France), AS Cottereau (France), M Federico (Italy), Gallamini (France), A Lister (UK), B Cheson (USA)**

Prognostic and predictive factors in lymphoma (10 min, A Lister)

PET metrics-based prognostic model for DLBCL Swiss data (10 min, L.Ceriani)

PET metrics-based prognostic model French data (10 min, C.Thieblemont)

PET driven DLBCL studies (10min, B Cheson)

Discussion between chair and panel

## **Saturday September 11<sup>th</sup>**

### **Afternoon sessions (on-line)**

## **4.00-5.00 Is artificial intelligence helpful (MV measurement and risk identification)?**

**Chair: T El-Galaly (Denmark), I Buvat (France), L Kostakoglu (USA)**

**Panel: N Capobianco, J Paulson, AS Cottereau**

Roche presentation: Gallium and Goya.

N Capobianco: the PARS method

I Buvat: Clinical risk models

L Kostakoglu: AI in nuclear medicine from a clinical perspective

## **5.00-6.00 Perspectives in Radiomics**

**Chair: R.Boellaard (The Netherlands), S Chauvie (Italy)**

**AS Cottereau (France) I Buvat (France): 30min.**

Discussion (audience and chair): 30 min

## **Break**

### **Evening sessions (on-line)**

**7.00-9.00 Poster discussion and best poster award.**

**U Duhrsen (Germany), T Vander Borgh (Belgium)**, summary of the poster and oral presentations and **Alberto Biggi award (introduction: A Gallamini, S Chauvie; awards ceremony: M Meignan, A Gallamini, U Duhrsen, T Vander Borgh)**.

**9.00-10.00 Perspectives and Conclusions**

**Chair: M Federico (Italy), H Tilly (France), A Lister (UK)**

**B Cheson (USA)**: PET in lymphoma during the last ten years. Perspectives from the meeting: 30min

Discussion (audience): 15 min

**M Meignan (France)** : slide summary of the open questions for the next meeting: 15 min.